Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. tumourprint

TUMOURPRINT SIGNED

High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 TUMOURPRINT project word cloud

Explore the words cloud of the TUMOURPRINT project. It provides you a very rough idea of what is the project "TUMOURPRINT" about.

2016    failed    unsatisfactory    bioprinters    combination    producing    animal    candidates    environment    constructs    automated    revolutionise    drug    bioinks    destructive    formulated    optimal    secured    exasperatingly    trials    tumour    microenvironment    18    oncology    ing    throughput    universal    drive    robotics    cells    precise    tumourprint    2d    mono    pharmaceutical    successfully    first    humans    mimicking    fold    world    ten    designed    analytical    clinical    record    disruptive    cultures    proposition    outcomes    economic    cell    attrition    fidel    unparalleled    scoring    commercialized    printed    willingness    live    3d    rely    capacity    pay    countries    commercialising    specially    completely    collaborations    implications    models    commercialise    hydrogels    platform    offers    none    commercialised    ethically    grown    proper    rates    generations    cancer    reproducible    tissue    proven    constitutes    global    bioprinting    establishment    predict    fabricating    market    track    printing    company    principally    serial    organisation    instructive    cellink    survival    heterogeneity    giants    vascularity    size    bioink    human   

Project "TUMOURPRINT" data sheet

The following table provides information about the project.

Coordinator		 CELLINK AB 

Organization address
address: ARVID WALLGRENS BACKE 20
city: GOTEBORG
postcode: 413 46
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Sweden [SE]
 Project website https://cellink.com/global/
 Total cost 3˙500˙467 €
 EC max contribution 2˙450˙327 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2021-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CELLINK AB SE (GOTEBORG) coordinator 2˙450˙327.00

Map

 Project objective

CELLINK will develop and commercialise TumourPrint - a high throughput platform for bioprinting of live tumour models for pharmaceutical drug development and large-scale cancer research. Bioprinting constitutes the most advanced method for fabricating fidel tissue models, using live cells in combination with cell-instructive bioinks (specially formulated hydrogels that provide cells with an optimal environment for survival, growth and proper 3D development).

The high throughput platform - completely new to the market - is designed according to user needs. It will revolutionise drug development processes through serial production of fidel cancer models in an automated, precise and reproducible way. The platform offers unparalleled printing capacity and is integrated with robotics and none-destructive analytical methods capable of scoring drug responses in printed constructs.

Current oncology approaches principally rely on unsatisfactory 2D mono-cell cultures and animal models to predict outcomes in humans, resulting in exasperatingly high attrition rates of cancer drug candidates in clinical trials. The economic and ethically challenging implications of failed trials provide CELLINK with a unique value proposition to drive willingness-to-pay for their disruptive platform. TumourPrint will address today’s pharmaceutical challenges by producing tumour models capable of mimicking size, heterogeneity and vascularity of the human tumour microenvironment in a fidel way.

CELLINK has a proven track-record of successfully developing and commercialising products according to user needs; they developed the world’s first universal bioink, have commercialized three generations of bioprinters and optimised 18 cell-specific bioinks. Since the company’s establishment in 2016, CELLINK has commercialised its technology in over 40 countries, grown its organisation ten-fold and secured collaborations with several global pharmaceutical giants.

 Deliverables

List of deliverables.
Cancer cell lines selected Documents, reports 2019-11-28 17:30:38
10 hired employees Demonstrators, pilots, prototypes 2019-11-28 17:30:39

Take a look to the deliverables list in detail:  detailed list of TUMOURPRINT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TUMOURPRINT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TUMOURPRINT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

CAARESYS (2019)

CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.

Read More  

Click and Spray (2020)

A SIMPLER, CHEAPER AND EASIER TO RECYCLE AEROSOL CONTAINER

Read More